Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KLRS
Strong SellSinkerKalaris Therapeutics, Inc. · Healthcare · United States · $96M · Avg Vol: $205K/d
COMPANY DESCRIPTION
Kalaris Therapeutics, Inc. is an early-stage biotechnology company focused on discovering and developing novel therapeutic candidates for unmet medical needs. Its competitive position relies on proprietary intellectual property surrounding its drug candidates and scientific expertise in specific disease pathways. As a preclinical-stage firm, Kalaris Therapeutics represents a speculative healthcare venture, where valuation is driven by pipeline potential and scientific breakthroughs rather than current revenue.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 11.4M | — |
| EPS | -11.64 | -11.05 | -3.70 | -2.85 | — | -1.90 | -2.01 | -1.66 | — |
| Shares | 18.7M | 18.7M | 18.7M | 22.9M | +22.5% | 23.8M | — | — | — |
| Debt | 3.3M | — | 19.5M | 1.4M | -23.6% | 1.4M | — | — | — |
| Equity | -30.3M | -45.0M | -96.6M | 78.8M | — | — | — | — | — |
| Op CF | -9.8M | -14.1M | -20.7M | -38.4M | — | -41.0M | — | — | — |
| Inv CF | — | — | 0 | -19.7M | — | — | — | — | — |
| Fin CF | 12.8M | 14.2M | 19.1M | 155.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KLRS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KLRS | Kalaris Therapeutics, Inc.(you) | $96M | 7 | Strong Sell |
| VRCA | Verrica Pharmaceuticals Inc. | $98M | 8 | Strong Sell |
| DWTX | Dogwood Therapeutics, Inc. | $90M | 9 | Strong Sell |
| PLYX | Polaryx Therapeutics, Inc. | $103M | 5 | Strong Sell |
| ONCY | Oncolytics Biotech Inc. | $109M | 6 | Strong Sell |
| ALDX | Aldeyra Therapeutics, Inc. | $90M | 4 | Strong Sell |
| RANI | Rani Therapeutics Holdings, Inc. | $118M | 7 | Strong Sell |
| CING | Cingulate Inc. | $77M | 7 | Strong Sell |
| GANX | Gain Therapeutics, Inc. | $77M | 7 | Strong Sell |
| COYA | Coya Therapeutics, Inc. | $108M | 10 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%